Virus

ElevateBio Gets $150M to Grow a Crop of Gene & Cell Therapy Startups

4 monthes ago   |   By Xconomy

When a biotech startup is ready to test an experimental therapy it faces a pricey choice: Should it make its drug in-house, or hire a contract manufacturer? The decision is particularly expensive for companies developing complex gene and cell therapies, which need to make large batches of engineered viruses to test their work. A new Cambridge, MA, company called ElevateBio aims to offer an alternative path. ElevateBio is building a facility that is intended to manufacture experimental gene and cell therapies for multiple startups, and aims to invest in those companies and help them grow...
Read more ...

 


Search by Tags

   Virus      Therapies      Genes      Gene      Manufacturing      BioTech      Biotech      Drug      Drugs      Engineering      Boston      Boston blog main      Boston top stories      National blog main      National top stories      New York blog main      Raleigh-Durham blog main      San Francisco blog main      Beta-Thalassemia      Biogen      BlueBird Bio      Brammer Bio      Cancer      Catalent      Cell Therapy      Clinical trials      David Hallal      EcoR1 Capital      ElevateBio      F2 Ventures      FDA      Gene Therapy      Hemophilia      Investing      Johnson & Johnson      Life Sciences      Mitch Finer      MPM Capital      Novartis      Paragon Bioservices      Pfizer      Redmile Group      Roche      Samsara BioCapital      Startups      UBS Oncology Investment Fund      Venture Capital      Zolgensma  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

An Entrepreneur's Quest to Make Seattle a Genome Sciences Hub

An Entrepreneur's Quest to Make Seattle a Genome Sciences Hub

Ivan Liachko turned postdoctoral research at the University of Washington into a company whose genomics tools are now found in laboratories researching human, animal, and plant... Read more ...

Flagship's Omega Aims to Take Epigenetic Drugs a Step Further

Flagship's Omega Aims to Take Epigenetic Drugs a Step Further

A biotech startup called Omega Therapeutics debuts this morning touting a new approach to developing medicines based on epigenetics, a field of research that has tantalized... Read more ...

Strip Steak: Bacterial Enzyme Removes Inflammation-Causing Meat Carbohydrates

Read more ...

Perturbed Genes Regulating White Blood Cells Linked to Autism Genetics and...

Read more ...

Ionis subsidiary Akcea ousts leadership team

Biotech veteran Damien McDevitt takes over as interim CEO... Read more ...

Enough with the Insanity. We Need to Fix Cybersecurity Now

The year 2019 has been another dreadful period for cyberattacks. The most notorious lowlights include: -More than 40 municipalities , including Baltimore, Albany and 22 cities... Read more ...

Why the lettuce mitochondrial genome is like a chopped salad

The mitochondrion, "the powerhouse of the cell." Somewhere back in the very distant past, something like a bacterium moved into another cell and never left, retaining some of... Read more ...

DNA is held together by hydrophobic forces

Researchers at Chalmers University of Technology, Sweden, have disproved the prevailing theory of how DNA binds itself. It is not, as is generally believed, hydrogen bonds... Read more ...

Gene therapy startup Passage Bio nabs Janssen neuro lead as CMO

Mere weeks after getting off a major $110 million series B round, well-funded Passage Bio has grabbed a new C-suite member on top of its cash haul. Read more ...

Clovis strikes 3B deal to move into radiopharmaceuticals

Clovis Oncology has paid $12 million for rights to FAP-targeted radiopharmaceuticals in development at 3B Pharmaceuticals. The deal gives Clovis the ex-Europe rights to a... Read more ...